The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hulbert, C.
Right arrow Articles by Thomas, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hulbert, C.
Right arrow Articles by Thomas, J. W.
The Journal of Immunology, 2001, 167: 5535-5538.
Copyright © 2001 by The American Association of Immunologists

Cutting Edge

Cutting Edge: B Cell Specificity Contributes to the Outcome of Diabetes in Nonobese Diabetic Mice1

Chrys Hulbert, Brent Riseili, Mauricio Rojas and James W. Thomas2

Departments of Medicine, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Type I diabetes mellitus (TIDM) is an autoimmune disorder characterized by T cell-mediated destruction of insulin-producing {beta} cells in the pancreas. In the nonobese diabetic (NOD) model of TIDM, insulitis and diabetes are dependent on the presence of B lymphocytes; however, the requirement for specificity within the B cell repertoire is not known. To determine the role of Ag-specific B cells in TIDM, VH genes with different potential for insulin binding were introduced into NOD as H chain transgenes. VH125 H chain combines with endogenous L chains to produce a repertoire in which 1–3% of mature B cells are insulin specific, and these mice develop accelerated diabetes. In contrast, NOD mice harboring a similar transgene, VH281, with limited insulin binding develop insulitis but are protected from TIDM. The data indicate that Ag-specific components in the B cell repertoire may alter the course of TIDM.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Type I diabetes mellitus (TIDM)3 is an organ-specific autoimmune disease that results from the loss of insulin-producing {beta} cells in the pancreatic islets. Many aspects of the human disease are shared with the nonobese diabetic (NOD) mouse model of the disorder, including a role for class II MHC polymorphisms (1, 2), T lymphocytes in the pancreatic infiltrates (3), and shared T cell regulatory abnormalities (4, 5). These observations and the ability of T cells to transfer the disease in NOD focus most studies on T lymphocytes. However, loss of tolerance in the B cell compartment, as manifested by the detection of autoantibodies to {beta} cell Ags, is one of the earliest indicators of TIDM. Among these, insulin autoantibodies have predictive value in both NOD and human TIDM (3, 6, 7), and insulin-specific T cells can transfer disease in NOD (8).

Direct evidence for the importance of B lymphocytes in TIDM comes from NOD mice rendered deficient in B lymphocytes by homozygous disruption of membrane-Ig µ (µMT) (9, 10). Likewise, passive transfer of anti-IgM Ab that blocks B cell development is also effective at preventing insulitis and eliminating diabetes in NOD (11, 12). In B cell knockout mice, direct reconstitution with mature B cells was not possible because of the strong CTL response against donor B lymphocytes by µMT-NOD mice. When B cells were introduced using bone marrow chimeras, TIDM susceptibility was restored in the µMT animals while transfer of sera failed to show a role for circulating Ab in the disease (13). Although these studies clearly demonstrate the importance of B cells in the development of TIDM in NOD, there are no data on how specificity of the B cell receptor for Ag contributes to the process. The Ag receptors on B lymphocytes can capture low abundance Ag for presentation to T cells (14), and in vitro studies suggest that the Ag presenting function of B cells (15, 16) or specific Abs (17) is uniquely able to induce responses to islet Ags such as glutamic acid decarboxylase.

To examine the role of Ag-specific B lymphocytes in insulin-dependent diabetes mellitus (IDDM), we introduced VH genes related to anti-insulin mab125 into the germline of NOD mice as IgMa transgenes (Tg). In previous studies using site-directed mutagenesis, VH125 is shown to contain two amino acid replacements in CDRH2 that are necessary for insulin binding (18). VH281 is identical except for an unmutated CDRH2 and it has no measurable insulin binding when expressed as a soluble Ab (18). Thus, NOD mice harboring the VH125 Tg (VH125Tg) have a B cell repertoire with increased potential to bind insulin, while mice harboring the VH281 Tg (VH281Tg) have a repertoire with a decreased insulin-binding potential. Accordingly, we used these mice to examine the impact of the B cell repertoire on the development of insulitis and diabetes in NOD mice. The data show that skewing the B cell repertoire toward an islet Ag (i.e., insulin) promotes the development of diabetes, whereas a repertoire with impaired recognition of insulin limits the progression of the disease.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Production and monitoring of transgenic lines

Mice expressing IgMa H chain (HC) Tgs VH125 and VH281 were produced in C57BL/6 as previously described (19) and were introduced into NOD mice (Taconic Farms, Germantown, NY) by multiple backcrosses. After the sixth and eight backcrosses (N7 and N9, respectively), animals were genotyped using 40 oligonucleotide primer pairs (Research Genetics, Huntsville, AL) for 13 known diabetes susceptibility loci (9). The animals were found to be homozygous for all NOD alleles. To eliminate expression of B cells that escape allelic exclusion, NOD.MuMT mice were obtained from Dr. D. Serreze (The Jackson Laboratory, Bar Harbor, ME) and crossed with the HC-transgenic lines to produce F2 generations that carry HC Tgs in the presence (µMT-/+) or absence (µMT-/-) of endogenous B cells. The deficiency of endogenous B cells was confirmed by the lack of circulating IgMb in ELISA and by lack of IgMb B cells in FACS. Female mice were monitored for the development of diabetes for a period of 40 wk. Mice were considered to be diabetic if two consecutive blood sugars were >200 mg/dl. All animals were housed in facilities at Vanderbilt under specific pathogen-free conditions.

Immunoassays

Spleen cells or PBLs were analyzed using FACScan (BD Biosciences, Mountain View, CA) and mAb to B220 (6B2), IgMa (RS-3.1), and IgMb (AF6) (BD PharMingen, San Diego, CA). Insulin-binding B cells were identified using biotin-insulin (5 ng) and FITC-streptavidin (Sigma-Aldrich, St. Louis, MO) in FACScan (19). To exclude nonspecific interactions, insulin-specific B cells were identified by inhibition with unmodified human insulin (50 ng). Serum allotypes and specific Abs were measured in ELISA as described elsewhere (19).

Histology

Pancreata from transgenic NOD or nontransgenic littermates ages 6–40 wk were analyzed for the presence of islet infiltrates after Formalin fixation and H&E staining. Islets (25–50) were examined on nonsequential sections from each pancreas. Islets that had either peri-insulitis or insulitis were scored as positive for infiltration and the percentage of islets with infiltration was determined for each mouse.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
HC Tgs effectively exclude endogenous Ig in NOD mice

IgMa HC Tgs were introduced into NOD by multiple backcrosses and their expression was examined by flow cytometry. Representative histograms for NOD and VH125Tg NOD mice are shown in Fig. 1Go. B cells from nontransgenic NOD mice do not express IgMa (Fig. 1GoA) and are all IgMb+ (Fig. 1GoB). In contrast, >90% of B cells (B220+) in VH125Tg NOD mice express the IgMa Tg (Fig. 1GoC) and only a small number of endogenous IgMb B cells are present (Fig. 1GoD). As in B6 mice, Tg expression was stable for over 40 wk in NOD spleen (94 ± 4% IgMa, n = 11). Similar results were obtained in VH281Tg NOD mice, although the degree of allelic exclusion is less (82 ± 5% IgMa, n = 10).



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 1. Allelic exclusion of endogenous IgMb in NOD mice harboring Ig-Ma Tgs. Flow cytometry gated on B cells (B220+) using FITC anti-IgMa (A and C) or anti-IgMb (B and D). Nontransgenic NOD mice (A) do not express IgMa and are IgMb+ (B). NOD mice harboring VH125HC show expression of IgMa (C) and exclusion of IgMb (D).

 
A B cell repertoire that favors insulin binding promotes the development of diabetes in NOD mice

To determine how B cell repertoires with different potentials for insulin binding effect the development of diabetes in NOD mice, cohorts of HC-transgenic female mice and their nontransgenic littermates were monitored for hyperglycemia (Fig. 2Go). The data show that mice harboring VH125Tg (n = 22) develop diabetes at an accelerated rate compared with the other lines. Twenty-one of 22 mice (95%) in this cohort developed diabetes by 40 wk. In contrast, mice that express VH281Tg (n = 19) are protected from developing diabetes and only 3 of 19 mice (16%) in this cohort developed diabetes. The differences are not attributable to circulating insulin Abs produced by the Tgs which are negligible (OD < 0.05) in both lines. Additional studies from different founders and at later backcrosses have identical results and support the observation that a skewed B cell repertoire can alter the outcome of diabetes in NOD mice.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 2. Divergent outcomes for diabetes in NOD mice are associated with different Ig HC Tgs. Incidence of diabetes in cohorts of female mice carrying VH125HC Tg ({diamondsuit}, n = 22), VH281HC Tg ({blacksquare}, n = 19), and nontransgenic littermates ({blacktriangleup}, n = 40). VH125 contains mutations in CDRH2 that favor insulin binding while VH281 is unmutated. Mice were considered diabetic if two consecutive blood sugars were >200 mg/dl.

 
Ig HC-transgenic NOD mice develop insulitis and diabetes in the absence of endogenous B cells

Although VH281Tg NOD are protected from developing diabetes, by 40 wk all animals had extensive islet infiltrates. Since mice that carry Ig Tgs routinely have populations of endogenous B cells that escape allelic exclusion, this additional source of B cells may contribute to the development of disease in transgenic NOD. Therefore, studies on islet infiltration were conducted using mice that expressed HC Tg in the presence (µMT-/+) or absence (µMT-/-) of a fixed mutation in Ig-µ to eliminate endogenous B cells (Fig. 3Go). All NOD mice harboring HC Tgs showed evidence of islet infiltration in the late prediabetic period (14 wk) and at this time point the extent of disease (percentage of islets with infiltration) is only slightly less in VH281Tg compared with VH125Tg NOD mice. When pancreata were examined at an earlier time point (6 wk), differences in the incidence of infiltration are more apparent, VH125Tg (75–85%) vs VH281Tg (40–50%). The incidence of infiltration in each Tg line was not effected by the presence of the µMT mutation. However, the extent of involvement (percentage of islets infiltrated) was slightly greater in both VH125 and VH281Tg NOD mice when endogenous B cells are present (µMT+/-). Thus, the additional diversity provided by endogenous B cells may enhance islet infiltration in HC-transgenic NOD mice; however, the repertoire of VH281Tg.µMT-/- is sufficient to generate insulitis in the absence of endogenous B cells.



View larger version (52K):
[in this window]
[in a new window]
  		FIGURE 3. Islet cell infiltration in NOD mice harboring Ig HC Tgs. Cohorts (6 and 14 wk) of transgenic and nontransgenic NOD mice were examined for the presence of islet infiltration (peri-insulitis + insulitis). The percentage of mice with infiltration and the extent of infiltration are summarized in the histograms for each cohort (n = 12): {blacksquare}, 50–100% of islets infiltrated; , 10–50%; and {square}, 1–10%. VH125 and VH281 indicate the HC Tgs and µMT-/+ or µMT-/- indicate the presence or absence of endogenous B cells after introduction of the NOD.µMT mutant alleles.

 
To extend these studies, NOD female littermates that harbor the VH125Tg in the presence (µMT-/+, n = 15) or absence (µMT-/-, n = 10) of endogenous B cells were monitored for the development of diabetes. The results are shown in Fig. 4Go and indicate that mice whose HC repertoire is composed only of VH125 develop diabetes at a rate comparable to the original cohort. In the presence of endogenous B cells (VH125Tg.µMT-/+), the onset of diabetes occurs slightly earlier (12 wk) but the overall incidence compared with VH125Tg.µMT-/- NOD mice is similar by 17 wk. This outcome is consistent with the insulitis data and suggests that residual B cells escaping allelic exclusion have only a modest effect on diabetes development in VH125Tg.



View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 4. Incidence of diabetes in VH125Tg NOD mice is similar in the presence (•) or absence ({circ}) of endogenous B cells. VH125Tg NOD mice were intercrossed and then backcrossed with NOD.µMT to produce cohorts of female mice without endogenous B cells (µMT-/-, n = 10) or without endogenous B cells (µMT-/+, n = 15).

 
Insulin-specific B cells are increased in mice harboring VH125Tg

To characterize the functional potential of the B cell repertoire of nontransgenic and HC-transgenic NOD mice, spleens were examined for insulin binding (Fig. 5Go). In nontransgenic NOD mice, some insulin-binding B cells are observed (Fig. 5GoA); however, binding is dim (mean fluorescence intensity, <200) and principally in B220-low or -negative regions. This binding is not Ag specific as indicated by the inability of insulin to inhibit binding (Fig. 5GoB). Low levels of noninhibitable insulin binding are also seen in spleens from VH281Tg mice (Fig. 5Go, C and D). The insulin-binding profile of B cells was different in VH125Tg mice (Fig. 5Go, E and F). In these mice, a distinct population of B220+ cells is shown to bind insulin (mean fluorescence intensity, >200; Fig, 5E), and inhibition with soluble insulin (Fig. 5GoF) indicates binding is specific. This population accounts for 3.1 ± 1.3% of B220+ cells in VH125Tg NOD mice (n = 9). Insulin-specific B cells were uniformly IgMa+ and similar results were obtained in mice with the µMT mutation (data not shown). Insulin-specific cells were very rare in VH281Tg NOD (1 of 9 at 0.5%) and in nontransgenic NOD (1 of 21 at 0.6%). Since NOD mice are known to produce insulin Abs (7), we interpret these findings to indicate that the frequency of insulin-specific B cell is increased at least 10–20 times in VH125Tg compared with nontransgenic NOD mice. This finding in NOD mice differs from our observations in B6 mice harboring VH125Tg where insulin-specific B cells were not observed (19).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 5. Increased frequency of insulin-specific B cells in NOD mice harboring the VH125 Tg. Insulin-binding B cells (B220-PE+) in spleen are identified using biotin-insulin (5 ng/ml) and FITC-avidin in flow cytometry (A, C, and E). Insulin-specific binding is indicated by inhibition with 50 ng/ml human insulin (B, D, and F). The percentage of B220+ cells binding insulin is indicated in the upper right quadrant. A and B, Nontransgenic NOD; C and D, VH281Tg; and D and E, VH125Tg.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, NOD mice harboring Ig HC Tgs are used to examine the role of Ag-specific B cells in TIDM. In these mice, B cell receptor usage is limited to a single HC VDJ while maintaining the potential for diversity at the L chain locus. The data show the importance of Ag-specific B cells in the development of diabetes in NOD mice and reveal that divergent outcomes for diabetes may be determined by differences in the B cell repertoire. A repertoire skewed toward insulin binding in VH125Tg mice favors the selection of insulin-specific B cells into the peripheral repertoire of NOD mice. These events may be obscure in nontransgenic NOD but are detectable in VH125Tg NOD because of the increased frequency of trackable B cells. Furthermore, B6 mice that express the same VH125 HC Tg do not demonstrate an increase in insulin-binding B cells over background (19); thus, the entry of insulin-specific B cells into the repertoire represents a breach of tolerance in the B cell compartment of NOD that is unmasked by the availability of the VH125 HC Tg. This observation is analogous to the presence of high-affinity insulin autoantibodies in human pre-IDDM that is linked to progressive {beta} cell destruction (7, 20). Thus, the selection of insulin-specific B cells into the repertoire of VH125Tg NOD and the differentiation of B cells to produce high-affinity IgG anti-insulin Ab in human pre-IDDM are similar processes that denote a critical threshold for {beta} cell destruction has been reached. Since our fixed HC Tgs do not produce measurable insulin Abs, the role of anti-insulin B cells may be as APCs to expand insulin-specific T cells which are known to contribute to TIDM (8).

In contrast, a B cell repertoire that is impaired for insulin binding by a HC Tg that differs in two amino acids protects VH281Tg NOD mice from diabetes. These mice, however, still develop islet infiltration (both peri-insulitis and insulitis). Since Ig Tgs do not completely exclude the expression of endogenous B cells (IgMb) that may include other specificities, we intercrossed our HC-transgenic NOD with B cell-deficient NOD.µMT to examine the role of endogenous B cells. The data show that additional diversity provided by residual endogenous B cells contributes modestly to insulitis in VH281Tg NOD; however, insulitis develops when VH281 is the only HC available. Likewise in VH125Tg mice, endogenous B cells may have a small effect on insulitis and diabetes but the overall outcome is determined principally by the function of the Tg. Recent studies examining anti-hen egg lysozyme Tgs in NOD also show the protection from diabetes in the presence of insulitis (D. Serreze, unpublished data). This observation is consistent with the data in VH281Tg NOD and indicate that a B cell repertoire with impaired recognition of islet Ags has limited the progression of diabetes. Ag-specific B cells may not be required for early islet infiltration but their presence may be associated with enhanced {beta} cell destruction. The current findings suggest that diverting even a small portion of the B cell repertoire may be beneficial in preserving {beta} cell function. Since insulin is only one of several autoantigens in TIDM, the approach may be readily extended to other islet Ags in the future.


   Acknowledgments
 
We are grateful to Dr. David Serreze for making NOD.MuMT mice available for this study and for sharing prepublication data. We thank Drs. Tom Aune, Nancy Olsen, and Peggy Kendall for their critical reviews of this manuscript.


   Footnotes
 
1 This work was supported in part by Grants DK43911 and AI47763 from the National Institutes of Health and by the Juvenile Diabetes Foundation. B.R. was supported by the Diabetes and Endocrine Research and Training Center student research program. Back

2 Address correspondence and reprint requests to Dr. James W. Thomas, T-3219 MCN Vanderbilt University, Nashville, TN 37232-2681. E-mail address: James. Thomas{at}mcmail.vanderbilt.edu Back

3 Abbreviations used in this paper: TIDM, type I diabetes mellitus; IDMM, insulin-dependent diabetes mellitus; HC, H chain; VH125, variable region HC gene from mAb125; VH281, unmutated HC progenitor of mAb125; NOD, nonobese diabetic; Tg, transgene; µMT, homozygous disruption of membrane IgM. Back

Received for publication August 6, 2001. Accepted for publication September 20, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Todd, J. A., J. I. Bell, H. O. McDevitt. 1987. HLA-DQb gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329:599.[Medline]
  2. Wicker, L. S., J. A. Todd, L. B. Peterson. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13:179.[Medline]
  3. Castaño, L., G. S. Eisenbarth. 1990. Type I diabetes: a chronic autoimmune disease of human, mouse and rat. Annu. Rev. Immunol. 8:647.[Medline]
  4. Delovitch, T. L., B. Singh. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727.[Medline]
  5. Wilson, S. B., S. C. Kent, T. K T. Patton, R. A. Orban, M. Jackson, S. Exley, D. A. Porcelli, M. A. Schatz, S. P. Atkinson, S. P. Balk, et al 1998. Extreme Th1 bias of invariant V{alpha}24J{alpha}Q T cells in type 1 diabetes. Nature 391:177.[Medline]
  6. Verge, C. F., D. Stenger, E. Bonifacio, P. G. Colman, C. Pilcher, P. J. Bingley, G. S. Eisenbarth. 1998. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47:1857.[Abstract]
  7. Yu, L., D. T. Robles, N. Abiru, P. Kaur, M. Rewers, K. Kelemen, G. S. Eisenbarth. 2000. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. USA 97:1701.[Abstract/Free Full Text]
  8. Daniel, D., R. G. Gill, N. Schloot, D. Weggman. 1995. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1056.[Medline]
  9. Serreze, D. V., H. D. Chapman, D. S. Varnum, M. S. Hanson, P. C. Reifsnyder, S. D. Richard, S. A. Fleming, E. H. Leiter, L. D. Shultz. 1996. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 184:2049.[Abstract/Free Full Text]
  10. Akashi, T., S. Nagafuchi, K. Anzai, S. Kondo, D. Kitamura, D. Kitamura, S. Wakana, J. Ono, M. Kikuchi, T. Watanabe. 1997. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice. Int. Immunol. 9:1159.[Abstract/Free Full Text]
  11. Forsgren, S., A. Andersson, V. Hillorn, A. Soderstrom, D. Holmberg. 1991. Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Scand. J. Immunol. 34:445.[Medline]
  12. Noorchashm, H., N. Noorchashm, J. Kern, S. Y. Rostami, C. F. Barker, A. Naji. 1997. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46:941.[Abstract]
  13. Serreze, D. V., S. A. Fleming, H. D. Chapman, S. D. Richard, E. H. Leiter, R. M. Tisch. 1998. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 161:3912.[Abstract/Free Full Text]
  14. Lanzavecchia, A.. 1990. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8:537.
  15. Falcone, M., J. Lee, G. Patstone, B. Yeung, N. Sarvetnick. 1998. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J. Immunol. 161:1163.[Abstract/Free Full Text]
  16. Noorchashm, H., Y. K. Lieu, N. Noorchashm, S. Y. Rostami, S. A. Greeley, A. Schlachterman, H. K. Song, L. E. Noto, A. M. Jevikar, C. F. Barker, A. Naji. 1999. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet {beta} cells of nonobese diabetic mice. J. Immunol. 163:743.[Abstract/Free Full Text]
  17. Reijonen, H., T. L. Daniels, A. Lernmark, G. T. Nepom. 2000. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 49:1621.[Abstract]
  18. Thomas, J. W., C. Hulbert. 1996. Somatically mutated B-cell pool provides precursors for insulin antibodies. J. Immunol. 157:763.[Abstract]
  19. Rojas, M., C. Hulbert, J. W. Thomas. 2001. Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen. J. Immunol. 166:3194.[Abstract/Free Full Text]
  20. Ziegler, A. G., M. Hummel, M. Schenker, E. Bonifacio. 1999. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460.[Abstract]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. Xiu, C. P. Wong, J.-D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder
B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in Fc{gamma}R Effector Functions
J. Immunol., March 1, 2008; 180(5): 2863 - 2875.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Bour-Jordan, B. L. Salomon, H. L. Thompson, R. Santos, A. K. Abbas, and J. A. Bluestone
Constitutive Expression of B7-1 on B Cells Uncovers Autoimmunity toward the B Cell Compartment in the Nonobese Diabetic Mouse
J. Immunol., July 15, 2007; 179(2): 1004 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. L. Kendall, G. Yu, E. J. Woodward, and J. W. Thomas
Tertiary Lymphoid Structures in the Pancreas Promote Selection of B Lymphocytes in Autoimmune Diabetes
J. Immunol., May 1, 2007; 178(9): 5643 - 5651.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Gilbert, D. G. Carnathan, P. C. Cogswell, L. Lin, A. S. Baldwin Jr, and B. J. Vilen
Dendritic Cells from Lupus-Prone Mice Are Defective in Repressing Immunoglobulin Secretion
J. Immunol., April 15, 2007; 178(8): 4803 - 4810.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. A. Silveira, H. D. Chapman, J. Stolp, E. Johnson, S. L. Cox, K. Hunter, L. S. Wicker, and D. V. Serreze
Genes within the Idd5 and Idd9/11 Diabetes Susceptibility Loci Affect the Pathogenic Activity of B Cells in Nonobese Diabetic Mice
J. Immunol., November 15, 2006; 177(10): 7033 - 7041.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. A. Acevedo-Suarez, D. M. Kilkenny, M. B. Reich, and J. W. Thomas
Impaired Intracellular Calcium Mobilization and NFATc1 Availability in Tolerant Anti-Insulin B Cells
J. Immunol., August 15, 2006; 177(4): 2234 - 2241.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Tian, D. Zekzer, Y. Lu, H. Dang, and D. L. Kaufman
B Cells Are Crucial for Determinant Spreading of T Cell Autoimmunity among beta Cell Antigens in Diabetes-Prone Nonobese Diabetic Mice
J. Immunol., February 15, 2006; 176(4): 2654 - 2661.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. J. Woodward and J. W. Thomas
Multiple Germline {kappa} Light Chains Generate Anti-Insulin B Cells in Nonobese Diabetic Mice
J. Immunol., July 15, 2005; 175(2): 1073 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Sblattero, F. Maurano, G. Mazzarella, M. Rossi, S. Auricchio, F. Florian, F. Ziberna, A. Tommasini, T. Not, A. Ventura, et al.
Characterization of the Anti-Tissue Transglutaminase Antibody Response in Nonobese Diabetic Mice
J. Immunol., May 1, 2005; 174(9): 5830 - 5836.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. A. Acevedo-Suarez, C. Hulbert, E. J. Woodward, and J. W. Thomas
Uncoupling of Anergy from Developmental Arrest in Anti-Insulin B Cells Supports the Development of Autoimmune Diabetes
J. Immunol., January 15, 2005; 174(2): 827 - 833.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. S. Wong, L. Wen, M. Tang, M. Ramanathan, I. Visintin, J. Daugherty, L. G. Hannum, C. A. Janeway Jr, and M. J. Shlomchik
Investigation of the Role of B-Cells in Type 1 Diabetes in the NOD Mouse
Diabetes, October 1, 2004; 53(10): 2581 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. A. Silveira, J. Dombrowsky, E. Johnson, H. D. Chapman, D. Nemazee, and D. V. Serreze
B Cell Selection Defects Underlie the Development of Diabetogenic APCs in Nonobese Diabetic Mice
J. Immunol., April 15, 2004; 172(8): 5086 - 5094.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. W. Thomas, P. L. Kendall, and H. G. Mitchell
The Natural Autoantibody Repertoire of Nonobese Diabetic Mice Is Highly Active
J. Immunol., December 1, 2002; 169(11): 6617 - 6624.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. Jaume, S. L. Parry, A.-M. Madec, G. Sonderstrup, and S. Baekkeskov
Suppressive Effect of Glutamic Acid Decarboxylase 65-Specific Autoimmune B Lymphocytes on Processing of T Cell Determinants Located Within the Antibody Epitope
J. Immunol., July 15, 2002; 169(2): 665 - 672.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hulbert, C.
Right arrow Articles by Thomas, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hulbert, C.
Right arrow Articles by Thomas, J. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS